Second-trimester Abortion.


Journal

Clinical obstetrics and gynecology
ISSN: 1532-5520
Titre abrégé: Clin Obstet Gynecol
Pays: United States
ID NLM: 0070014

Informations de publication

Date de publication:
01 Dec 2023
Historique:
medline: 16 11 2023
pubmed: 1 11 2023
entrez: 1 11 2023
Statut: ppublish

Résumé

In 2019, the US Centers for Disease Control reported that 7% of abortions were performed after 13 weeks of pregnancy, a small proportion of all terminations. However, the need for second-trimester abortions will increase commensurate with restrictions to access nationwide. Second-trimester abortions are performed with medications or through a procedure. Health care practitioners serving persons at risk of pregnancy should understand how abortions are performed and how to deliver evidence-based postabortion care. The purpose of this article is to provide a foundation for caring for individuals before, during, and after second-trimester abortion.

Identifiants

pubmed: 37910075
doi: 10.1097/GRF.0000000000000825
pii: 00003081-990000000-00114
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

685-697

Informations de copyright

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Références

Kortsmit K, Nguyen AT, Mandel MG, et al. Abortion surveillance—United States, 2020. MMWR Surveill Summ. 2022;71(SS-10):1–27.
American College of Obstetricians and Gynecologists Second-trimester abortion. ACOG Practice Bulletin No. 135. Obstet Gynecol. 2013;121:1394–1406.
Foster DG, Biggs MA, Ralph L, et al. Socioeconomic outcomes of women who receive and women who are denied wanted abortions in the Untied States. Am J Public Health. 2018;108:407–413.
Guttmacher Institute Bans on specific abortion methods used after the first trimester. Accessed June 1, 2023. https://www.guttmacher.org/state-policy/explore/bans-specific-abortion-methods-used-after-first-trimester
Roberts SCM, Upadhyay UD, Liu G, et al. Association of facility type with procedural-related morbidities and adverse events among patients undergoing induced abortions. JAMA. 2018;319:2497–2506.
Chasen ST, Kalish RB, Gupta M, et al. Dilation and evacuation at ≥20 weeks: comparison of operative techniques. Am J Obstet Gynecol. 2004;190:1180–1183.
Autry AM, Hayes EC, Jacobson GF, et al. A comparison of medical induction and dilation and evacuation for second-trimester abortion. Am J Obstet Gynecol. 2002;187:393–397.
Bryant AG, Grimes DA, Garrett JM, et al. Second-trimester abortion for fetal anomalies or fetal death: labor induction compared with dilation and evacuation. Obstet Gynecol. 2011;117:788–792.
Sonalkar S, Ogden SN, Tran LK, et al. Comparison of complications associated with induction by misoprostol versus dilation and evacuation for second-trimester abortion. Int J Gynecol Obstet. 2017;138:272–275.
Kerns J, Steinauer J. Management of postabortion hemorrhage. Contraception. 2013;87:331–342.
Kerns JL, Ti A, Aksel S, et al. Disseminated intravascular coagulation and hemorrhage after dilation and evacuation abortion for fetal death. Obstet Gynecol. 2019;134:708–713.
O’Connell K, Jones HE, Simon M, et al. First-trimester surgical abortion practices: a survey of National Abortion Federation members. Contraception. 2009;79:385–392.
Kim R, Pelletier A, Donnenfeld B, et al. Safety of deep sedation without intubation during surgical abortion in the independent clinic setting. Contraception. 2020;101:298–301.
Achilles SL, Reeves MF. Prevention of infection after induced abortion. Contraception. 2011;83:295–309.
Edelman A, Kapp N. Dilation and Evacuation (D&E) Reference Guide: Induced Abortion and Postabortion Care at or after 13 Weeks Gestation (‘second Trimester’). IPAS; 2018.
Grossman D, Blanchard K, Blumenthal P. Complications after second trimester surgical and medical abortion. Reprod Health Matters. 2008;16:173–182.
Lichtenberg ES. Complications of osmotic dilators. Obstet Gynecol Surv. 2004;59:528–536.
Fox MC, Krajewski CM. Cervical preparation for second-trimester surgical abortion prior to 20 weeks’ gestation. Contraception. 2014;89:75–84.
Diedrich JT, Drey EA, Newmann SJ. Society of Family Planning clinical recommendations: cervical preparation for dilation and evacuation at 20–24 weeks’ gestation. Contraception. 2020;101:286–292.
Fraz F, Hou MY. Mechanical dilation to remove incarcerated laminaria during a second trimester abortion. Contraception. 2021;103:284–286.
Soon R, Tschann M, Salcedo J, et al. Paracervical block for laminaria insertion before second-trimester abortion: a randomized controlled trial. Obstet Gynecol. 2017;130:387–392.
Allanson ER, Copson S, Spilsbury K. Pretreatment with mifepristone compared with misoprostol alone for delivery after fetal death between 14 and 28 weeks of gestation: a randomized controlled trial. Obstet Gynecol. 2021;137:801–809.
Perritt JB, Burke A, Edelman AB. Interruption of nonviable pregnancies of 24–28 weeks’ gestation using medical methods. Contraception. 2013;88:341–349.
Wingo E, Raifman S, Landau C, et al. Mifepristone–misoprostol versus misoprostol-alone regimen for medication abortion at ≥24 weeks’ gestation. Contraception. 2020;102:99–103.
Borgatta L, Kapp N. Labor induction abortion in the second trimester. Contraception. 2011;84:4–18.
Hammond C, Chasen S. Dilation and evacuation. Management of Unintended and Abnormal Pregnancy. John Wiley & Sons, Ltd; 2009:157–177.
Schulz KF, Grimes DA, Christensen DD. Vasopressin reduces blood loss from second-trimester dilatation and evacuation abortion. The Lancet. 1985;326:353–356.
Frick AC, Drey EA, Diedrich JT, et al. Effect of prior cesarean delivery on risk of second-trimester surgical abortion complications. Obstet Gynecol, 115:760–764.
Whitehouse K, Tschann M, Soon R, et al. Effects of prophylactic oxytocin on bleeding outcomes in women undergoing dilation and evacuation: a randomized controlled trial. Obstet Gynecol. 2019;133:484–491.
Grimes DA, Flock ML, Schulz KF, et al. Hysterectomy as treatment for complications of legal abortion. Obstet Gynecol. 1984;63:457–462.
Creinin MD, Blumenthal P, Shulman L. Mifepristone-misoprostol medical abortion mortality. Medscape Gen Med. 2006;8:26.
Elimian A, Verma U, Tejani N. Effect of causing fetal cardiac asystole on second-trimester abortion. Obstet Gynecol. 1999;94:139–141.
Jackson R, Teplin V, Drey E, et al. Digoxin to facilitate late second-trimester abortion: a randomized, masked, placebo-controlled trial. Obstet Gynecol. 2001;97:471–476.
Lee SJ, Ralston HJP, Drey EA, et al. Fetal pain—a systematic multidisciplinary review of the evidence. JAMA. 2005;294:947–954.
Molaei M, Jones HE, Weiselberg T, et al. Effectiveness and safety of digoxin to induce fetal demise prior to second-trimester abortion. Contraception. 2008;77:223–225.
Pasquini L, Pontello V, Kumar S. Intracardiac injection of potassium chloride as method for feticide: experience from a single UK tertiary centre. BJOG Int J Obstet Gynaecol. 2008;115:528–531.
Hern W. Laminaria, induced fetal demise and misoprostol in late abortion. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2002;75:279–286.
Mui SVLK, Chitrit Y, Boulanger MC, et al. Sepsis due to Clostridium perfringens after pregnancy termination with feticide by cordocentesis: a case report. Fetal Diagn Ther. 2002;17:124–126.
World Health Organization Abortion care guideline. 2022. https://www.who.int/publications/i/item/9789240039483
Henkel A, Johnson S, Cahill E, et al. Cabergoline for lactation inhibition after second-trimester abortion or loss: a randomized controlled trial. Contraception. 2022;116:70.
Prine LW, MacNaughton H. Office management of early pregnancy loss. Am Fam Physician. 2011;84:75–82.
Hu A. Reflections: the value of patient support groups. Otolaryngol Neck Surg. 2017;156:587–588.
Jones RK, Kirstein M, Philbin J. Abortion incidence and service availability in the United States, 2020. Perspect Sex Reprod Health. 2022;54:128–141.
Guttmacher Institute Induced abortion in the United States. Guttmacher Institute. Accessed September 3, 2023. https://www.guttmacher.org/fact-sheet/induced-abortion-united-states

Auteurs

Vanessa Swantic (V)

Department of Obstetrics and Gynecology, Morristown Medical Center, Morristown, New Jersey.

Darell Hawley (D)

Department of Family Medicine, Morristown Medical Center, Morristown, New Jersey.

Christopher Zipp (C)

Department of Family Medicine, Morristown Medical Center, Morristown, New Jersey.

Nancy Lee (N)

Department of Family Medicine, Morristown Medical Center, Morristown, New Jersey.

Piyapa Praditpan (P)

Department of Obstetrics and Gynecology, Morristown Medical Center, Morristown, New Jersey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH